Table 2.
Detail treatment protocols of PRP and HA injections
| Author | PRP | HA | |||||
|---|---|---|---|---|---|---|---|
| Injection dose (ml) | Times | Intervals | Type | Injection dose (ml) | Times | Intervals | |
| Ahmad 2018 [22] | 4 | 3 | 2 Weeks | LRP | 20 mg/2 ml high | 3 | 2 Weeks |
| Buendia-Lopez 2018 [23] | 5 | NS | NS | LPP | 60 mg/2 ml high | NS | NS |
| Cerza 2012 [24] | 5.5 | 4 | Weekly | LPP | 20 mg/2 ml high | 4 | Weekly |
| Cole 2017 [20] | 4 | 3 | Weekly | LPP | 16 mg/2 ml high (6 MDa) | 3 | Weekly |
| Di Martino 2019 [25] | 5 | 3 | Weekly | LRP | 30 mg/2 ml high (> 1500 kDa) | 3 | Weekly |
| Duymus 2017 [26] | 5 | 2 | Monthly | LRP | 40 mg/2 ml high (1600 kDa) | 1 | Monthly |
| Filardo 2015 [19] | 5 | 3 | Weekly | LRP | 30 mg/2 ml high (> 1500 kDa) | 3 | Weekly |
| Gormeli 2017 [27] | 5 | 3 | Weekly | LRP | 30 mg/2 ml | 3 | Weekly |
| Huang 2019 [28] | 2 | 3 | Weekly | LPP | 4 ml (500–730 kDa) | 3 | Weekly |
| Li 2011 [29] | 3.5 | 3 | 3 Weeks | LRP | 2 ml | 3 | 3 Weeks |
| Lin 2019 | 5 | 3 | Weekly | LPP | 20 mg/2 ml | 3 | Weekly |
| Louis 2018 [30] | 3 | 1 | NS | LPP | 60 mg/3 ml | 1 | NS |
| Montanez-Heredia 2016 [31] | NS | 3 | 2 Weeks | LPP | NS | 3 | 2 Weeks |
| Paterson 2016 [32] | 3 | 3 | Weekly | LRP | 3 ml | 3 | Weekly |
| Raeissadat 2015 [33] | 43,927 | 2 | Monthly | LRP | 20 mg/2 ml (500–730 kDa) | 3 | Weekly |
| Sanchez 2012 [34] | 8 | 3 | Weekly | LPP | NS | 3 | Weekly |
| Su 2018 [35] | 6 | 2 | 2 Weeks | LRP | 2 ml | 5 | Weekly |
| Vaquerizo 2013 [36] | 8 | 3 | 2 Weeks | LPP | NS | 1 | NS |
| Yu 2018 [37] | 2–14 | 4 | Weekly | LRP | 0.1–0.3 mg | 4 | Weekly |
| Tavassoli 2019 [38] | 4–6 | 4 | 3 Weeks | LRP | 30 mg/2 ml (500–730 kDa) | 4 | Weekly |